Eli Lilly and Company

lilly.com · Indianapolis, United States of America

Eli Lilly and Company is a global pharmaceutical manufacturer that discovers, develops, and commercializes prescription medicines across areas such as diabetes, oncology, immunology, neuroscience, and obesity. It sells its drugs to healthcare providers, hospitals, pharmacies, and governments worldwide through branded and, in some cases, partnered distribution channels. The company generates revenue primarily from patented therapeutics and related pharmaceutical products and collaborations.

Revenue
$1B+
Employees
5,001+
Founded
1876
Headquarters
Indianapolis, United States of America

Eli Lilly and Company customers on Arbolus

Total customers 12 12 current · 0 former
Reviews growth 7 new reviews since Jun 2026

Customers who reviewed Eli Lilly and Company

Seniority of Eli Lilly and Company customers

Most people who reviewed Eli Lilly and Company hold C-Suite roles (67%), followed by Director (25%) and Manager (8%).

  • C-Suite 67%
  • Director 25%
  • Manager 8%

Customers sample

Strategy Partner C-Suite NPS 9
Revenue Leader C-Suite NPS 10
Operations Ops C-Suite NPS 10 Undecided

Employer names and spend open once the report publishes.

What 12 Arbolus experts think of Eli Lilly and Company

Overall sentiment: Positive

NPS scores are highly positive, with 67% at 9 or above and no observed detractor scores. Renewal intent is mixed, as two Influencers indicate uncertainty despite high spend. Stickiness is strong, with 56% of responses indicating usage beyond one year and pilot activity indicating new expansion. Key themes are sustained user satisfaction and strong adoption at the operational level.

Tell us when the Eli Lilly and Company report publishes.

We'll email you once the full customer report is ready, with employer names, spend and every written answer. No account needed.

Sentiment

50 Net Promoter Score, from 12 scored reviews
  • Promoters 8
  • Passives 2
  • Detractors 2

Written answers and themes publish with the full report.

Renewal intent

Plan to renew 40%
  • Will renew 2
  • Undecided 2
  • Not renewing 1

Plan to renew, by seniority

  • C-Suite 33% 3 answers
  • Director 100% 1 answer
  • Manager 0% 1 answer
  • 8.5/10 Average score from customers who will renew
  • 8.5/10 Average score from undecided customers
  • 5/10 Average score from customers not renewing

For people who use Eli Lilly and Company

Do you use Eli Lilly and Company at work?

Share your software review and get matched to paid projects. Arbolus pays you every time a client reads your review.

  • 12 customers of Eli Lilly and Company have already contributed

Takes a few minutes. Your identity stays anonymous.